Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Collegium Pharmaceutical, Inc. COLL
$22.98
-$0.15 (-0.65%)
На 18:00, 12 мая 2023
+52.31%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
798793932.00000000
-
week52high
30.22
-
week52low
14.19
-
Revenue
463933000
-
P/E TTM
-31
-
Beta
0.80242200
-
EPS
-0.70000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 20:00
Описание компании
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Neutral | Buy | 08 авг 2022 г. |
| Needham | Buy | Buy | 06 апр 2022 г. |
| Piper Sandler | Overweight | Overweight | 22 февр 2022 г. |
| Needham | Buy | Buy | 15 февр 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 15 февр 2022 г. |
| Needham | Buy | Buy | 04 ноя 2022 г. |
| Needham | Buy | Buy | 05 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Dreyer Scott | D | 102798 | 69 | 09 янв 2023 г. |
| Dreyer Scott | D | 102867 | 7341 | 09 янв 2023 г. |
| Dreyer Scott | D | 110208 | 10424 | 09 янв 2023 г. |
| Ciaffoni Joseph | D | 248750 | 400 | 27 дек 2022 г. |
| Ciaffoni Joseph | D | 249150 | 1804 | 27 дек 2022 г. |
| Heffernan Michael Thomas | D | 0 | 3820 | 27 дек 2022 г. |
| Heffernan Michael Thomas | D | 3820 | 15995 | 27 дек 2022 г. |
| Heffernan Michael Thomas | D | 28023 | 3820 | 27 дек 2022 г. |
| Heffernan Michael Thomas | A | 31843 | 3820 | 27 дек 2022 г. |
| Heffernan Michael Thomas | A | 44018 | 15995 | 27 дек 2022 г. |
Новостная лента
Collegium Pharmaceutical, Inc. (COLL) Q1 2023 Earnings Call Transcript
Seeking Alpha
06 мая 2023 г. в 22:16
Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Christopher James - Vice President, Investor Relations Joe Ciaffoni - Chief Executive Officer Colleen Tupper - Chief Financial Officer Scott Dreyer - Chief Commercial Officer Conference Call Participants David Amsellem - Piper Sandler Tim Lugo - William Blair Brandon Folkes - Cantor Fitzgerald Serge Belanger - Needham & Company Greg Fraser - Truist Securities Glen Santangelo - Jefferies Operator Greetings and welcome to the Collegium Pharmaceutical First Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Collegium to Report First Quarter 2023 Financial Results on May 4, 2023
GlobeNewsWire
20 апр 2023 г. в 08:00
STOUGHTON, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report first quarter 2023 financial results after the market closes on Thursday, May 4, 2023. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET.
COLL vs. ZTS: Which Stock Should Value Investors Buy Now?
Zacks Investment Research
01 мар 2023 г. в 12:47
COLL vs. ZTS: Which Stock Is the Better Value Option?
Collegium Pharmaceutical, Inc. (COLL) Q4 2022 Earnings Call Transcript
Seeking Alpha
23 февр 2023 г. в 22:07
Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Christopher James - Vice President of Investor Relations at Collegium Pharmaceuticals Joe Ciaffoni - Chief Executive Officer Colleen Tupper - Chief Financial Officer Scott Dreyer - Chief Commercial Officer Conference Call Participants David Amsellem - Piper Sandler Brandon Folkes - Cantor Fitzgerald Serge Belanger - Needham & Company Greg Fraser - Truist Operator Greetings, and welcome to the Collegium Pharmaceutical Fourth Quarter and Full Year 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Beat Estimates
Zacks Investment Research
23 февр 2023 г. в 18:49
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 5.83% and 2%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?